These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 17846375)
21. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840 [TBL] [Abstract][Full Text] [Related]
22. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Viola F; Morescalchi F; Staurenghi G Arch Ophthalmol; 2006 Jan; 124(1):133-4. PubMed ID: 16401800 [No Abstract] [Full Text] [Related]
23. Persistent triamcinolone acetonide particles on the posterior lens capsule after intravitreal injection. Sakalar YB; Unlu K; Keklikci U; Caca I; Senol BB Ann Ophthalmol (Skokie); 2008; 40(3-4):190-2. PubMed ID: 19230363 [TBL] [Abstract][Full Text] [Related]
24. Acute glaucoma in a patient with an Artisan® due to trabecular blockage after combined intravitreal treatment for macular oedema. Valverde-Megías A; Donate-López J; Torres-Imaz R; Díaz Valle D; Arriola-Villalobos P; Jiménez-Santos M; García-Feijoo J Arch Soc Esp Oftalmol; 2013 Mar; 88(3):120-2. PubMed ID: 23473090 [TBL] [Abstract][Full Text] [Related]
25. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Moshfeghi AA; Scott IU; Flynn HW; Puliafito CA Am J Ophthalmol; 2004 Sep; 138(3):489-92. PubMed ID: 15364241 [TBL] [Abstract][Full Text] [Related]
26. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075 [TBL] [Abstract][Full Text] [Related]
27. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Jonas JB; Degenring RF; Kreissig I; Akkoyun I; Kamppeter BA Ophthalmology; 2005 Apr; 112(4):593-8. PubMed ID: 15808249 [TBL] [Abstract][Full Text] [Related]
28. Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Yang CS; Chen MJ; Chou CK; Hsu WM Ophthalmologica; 2005; 219(6):413-5. PubMed ID: 16286805 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Elbendary AM; Shahin MM Retina; 2011 Nov; 31(10):2058-64. PubMed ID: 21765371 [TBL] [Abstract][Full Text] [Related]
30. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion. Gokce G; Sobaci G; Durukan AH; Erdurman FC Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663 [TBL] [Abstract][Full Text] [Related]
32. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Vasconcelos-Santos DV; Nehemy PG; Schachat AP; Nehemy MB Retina; 2008 Apr; 28(4):573-80. PubMed ID: 18398360 [TBL] [Abstract][Full Text] [Related]
33. Intraocular availability of triamcinolone acetonide after intravitreal injection. Jonas JB Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884 [TBL] [Abstract][Full Text] [Related]
34. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Gregori NZ; Rosenfeld PJ; Puliafito CA; Flynn HW; Lee JE; Mavrofrides EC; Smiddy WE; Murray TG; Berrocal AM; Scott IU; Gregori G Retina; 2006 Oct; 26(8):889-95. PubMed ID: 17031288 [TBL] [Abstract][Full Text] [Related]
35. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Er H; Yilmaz H Ophthalmologica; 2005; 219(6):394-400. PubMed ID: 16286802 [TBL] [Abstract][Full Text] [Related]
36. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Thompson JT Am J Ophthalmol; 2006 Apr; 141(4):629-37. PubMed ID: 16564796 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Bae JH; Lee CS; Lee SC Retina; 2011 Jan; 31(1):111-8. PubMed ID: 20856170 [TBL] [Abstract][Full Text] [Related]
38. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Bonini-Filho MA; Jorge R; Barbosa JC; Calucci D; Cardillo JA; Costa RA Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3845-9. PubMed ID: 16186372 [TBL] [Abstract][Full Text] [Related]
39. Ocular morbidity associated with intravitreal triamcinolone acetonide. Konstantopoulos A; Williams CP; Newsom RS; Luff AJ Eye (Lond); 2007 Mar; 21(3):317-20. PubMed ID: 16710433 [TBL] [Abstract][Full Text] [Related]